Rapid Diagnosis of Tuberculosis with the Xpert MTB/RIF Assay in High Burden Countries: A Cost-Effectiveness Analysis

English version České info

Background:
Xpert MTB/RIF (Xpert) is a promising new rapid diagnostic technology for tuberculosis (TB) that has characteristics that suggest large-scale roll-out. However, because the test is expensive, there are concerns among TB program managers and policy makers regarding its affordability for low- and middle-income settings.

Methods and Findings:
We estimate the impact of the introduction of Xpert on the costs and cost-effectiveness of TB care using decision analytic modelling, comparing the introduction of Xpert to a base case of smear microscopy and clinical diagnosis in India, South Africa, and Uganda. The introduction of Xpert increases TB case finding in all three settings; from 72%–85% to 95%–99% of the cohort of individuals with suspected TB, compared to the base case. Diagnostic costs (including the costs of testing all individuals with suspected TB) also increase: from US$28–US$49 to US$133–US$146 and US$137–US$151 per TB case detected when Xpert is used “in addition to” and “as a replacement of” smear microscopy, respectively. The incremental cost effectiveness ratios (ICERs) for using Xpert “in addition to” smear microscopy, compared to the base case, range from US$41–$110 per disability adjusted life year (DALY) averted. Likewise the ICERS for using Xpert “as a replacement of” smear microscopy range from US$52–$138 per DALY averted. These ICERs are below the World Health Organization (WHO) willingness to pay threshold.

Conclusions:
Our results suggest that Xpert is a cost-effective method of TB diagnosis, compared to a base case of smear microscopy and clinical diagnosis of smear-negative TB in low- and middle-income settings where, with its ability to substantially increase case finding, it has important potential for improving TB diagnosis and control. The extent of cost-effectiveness gain to TB programmes from deploying Xpert is primarily dependent on current TB diagnostic practices. Further work is required during scale-up to validate these findings.

: Please see later in the article for the Editors' Summary

Vyšlo v časopise: Rapid Diagnosis of Tuberculosis with the Xpert MTB/RIF Assay in High Burden Countries: A Cost-Effectiveness Analysis. PLoS Med 8(11): e32767. doi:10.1371/journal.pmed.1001120
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001120

Souhrn

Zdroje

1. WHO | Global tuberculosis control 2010 (z.d.). Available: http://www.who.int/tb/publications/global_report/2010/en/index.html. Accessed 24 January 2011

2. BoehmeCCNicolMNabetaPMichaelJSGotuzzoE 2011 Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377 1495 1505

3. BoehmeCCNabetaPHillemannDNicolMPShenaiS 2010 Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363 1005 1015

4. DowdyDWO'BrienMABishaiD 2008 Cost-effectiveness of novel diagnostic tools for the diagnosis of tuberculosis. Int J Tuberc Lung Dis 12 1021 1029

5. DowdyDWLourençoMCCavalcanteSCSaraceniVKingB 2008 Impact and cost-effectiveness of culture for diagnosis of tuberculosis in HIV-infected Brazilian adults. PLoS ONE 3 e4057 doi:10.1371/journal.pone.0004057

6. Acuna-VillaordunaCVassallAHenostrozaGSeasCGuerraH 2008 Cost-effectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries. Clin Infect Dis 47 487 495

7. RoosBRvan CleeffMRGithuiWAKivihya-NduggaLOdhiamboJA 1998 Cost-effectiveness of the polymerase chain reaction versus smear examination for the diagnosis of tuberculosis in Kenya: a theoretical model. Int J Tuberc Lung Dis 2 235 241

8. WHO 2007 Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents. Recommendations for HIV-prevalent and resource-constrained settings Geneva World Health Organization

9. WHO | Guidelines for surveillance of drug resistance in tuberculosis (z.d.). Available: http://www.who.int/tb/publications/2009/surveillance_guidelines/en/index.html. Accessed 24 January 2011

10. WHO | Surveillance of drug resistance in tuberculosis (z.d.). Available: http://www.who.int/tb/publications/mdr_surveillance/en/index.html. Accessed 24 January 2011

11. LukoyeDCobelensFGJEzatiNKirimundaSAdatuFE 2011 Rates of anti-tuberculosis drug resistance in Kampala-Uganda are low and not associated with HIV infection. PLoS ONE 6 e16130 doi:10.1371/journal.pone.0016130

12. WHO | WHO-CHOICE (z.d.). Available: http://www.who.int/choice/en/. Accessed 18 April 2011

13. van CleeffMRAKivihya-NduggaLEMemeHOdhiamboJAKlatserPR 2005 The role and performance of chest X-ray for the diagnosis of tuberculosis: a cost-effectiveness analysis in Nairobi, Kenya. BMC Infect Dis 5 111

14. FloydKAroraVKMurthyKJRLonnrothKSinglaN 2006 Cost and cost-effectiveness of PPM-DOTS for tuberculosis control: evidence from India. Bull World Health Organ 84 437 445

15. OkelloDFloydKAdatuFOdekeRGargioniG 2003 Cost and cost-effectiveness of community-based care for tuberculosis patients in rural Uganda. Int J Tuberc Lung Dis 7 S72 S79

16. PantojaALönnrothKLalSSChauhanLSUplekarM 2009 Economic evaluation of public-private mix for tuberculosis care and control, India. Part II. Cost and cost-effectiveness. Int J Tuberc Lung Dis 13 705 712

17. SinanovicEFloydKDudleyLAzevedoVGrantR 2003 Cost and cost-effectiveness of community-based care for tuberculosis in Cape Town, South Africa. Int J Tuberc Lung Dis 7 S56 62

18. SinanovicEKumaranayakeL 2006 Financing and cost-effectiveness analysis of public-private partnerships: provision of tuberculosis treatment in South Africa. Cost Eff Resour Alloc 4 11 doi:10.1186/1478-7547-4-11

19. Tan-Torres EdejerTBRAdamTHutubessyRAcharyaAEvansDB 2003 WHO Guide to Cost-effectiveness Analysis Geneva World Health Organization

20. LewWPaiMOxladeOMartinDMenziesD 2008 Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med 149 123 134

21. EspinalMAKimSJSuarezPGKamKMKhomenkoAG 2000 Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 283 2537 2545

22. MenziesDBenedettiAPaydarARoyceSMadhukarP 2009 Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med 6 e1000150 doi:10.1371/journal.pmed.1000150

23. NathansonELambregts-van WeezenbeekCRichMLGuptaRBayonaJ 2006 Multidrug-resistant tuberculosis management in resource-limited settings. Emerging Infect Dis 12 1389 1397

24. AkksilpSKarnkawinpongOWattanaamornkiatWViriyakitjaDMonkongdeeP 2007 Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand. Emerging Infect Dis 13 1001 1007

25. VarmaJKNateniyomSAkksilpSMankatitthamWSirinakC 2009 HIV care and treatment factors associated with improved survival during TB treatment in Thailand: an observational study. BMC Infect Dis 9 42

26. WellsCDCegielskiJPNelsonLJLasersonKFHoltzTH 2007 HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis 196 Suppl 1 S86 S107

27. SeungKJOmatayoDBKeshavjeeSFurinJJFarmerPE 2009 Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. PLoS ONE 4 e7186 doi:10.1371/journal.pone.0007186

28. Abdool KarimSSNaidooKGroblerAPadayatchiNBaxterC 2010 Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 362 697 706

29. RiederHLEnarsonDA 1995 A computer-based ordering system for supplies in national tuberculosis programs. Tuber Lung Dis 76 450 454

30. MooreDAJEvansCAWGilmanRHCaviedesLCoronelJ 2006 Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med 355 1539 1550

31. VassallASemeACompernollePMeheusF 2010 Patient costs of accessing collaborative tuberculosis and human immunodeficiency virus interventions in Ethiopia. Int J Tuberc Lung Dis 14 604 610

32. HoltzTHKaberaGMthiyaneTZingoniTNadesanS 2011 Use of a WHO-recommended algorithm to reduce mortality in seriously ill patients with HIV infection and smear-negative pulmonary tuberculosis in South Africa: an observational cohort study. Lancet Infect Dis 11 533 540

33. ShillcuttSDWalkerDGGoodmanCAMillsAJ 2009 Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules. Pharmacoeconomics 27 903 917

34. DowdyDWCattamanchiASteingartKRPaiM 2011 Is scale-up worth it? Challenges in economic analysis of diagnostic tests for tuberculosis. PLoS Med 8 e1001063 doi:10.1371/journal.pmed.1001063

35. OberhelmanRASoto-CastellaresGGilmanRHCaviedesLCastilloME 2010 Diagnostic approaches for paediatric tuberculosis by use of different specimen types, culture methods, and PCR: a prospective case-control study. Lancet Infect Dis 10 612 620